PMC:3724972 / 11567-11955 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/3724972","sourcedb":"PMC","sourceid":"3724972","source_url":"https://www.ncbi.nlm.nih.gov/pmc/3724972","text":"Fig. 3 Changes in UFC levels from baseline to 6 months in individual patients in the phase 3 trial of pasireotide. The dashed black line represents the upper limit of the normal range for UFC. From Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, et al., for the Pasireotide B2305 Study Group (2012) N Engl J Med, volume 366, page 918 [43]. Reproduced with permission","divisions":[{"label":"label","span":{"begin":0,"end":6}}],"tracks":[{"project":"2_test","denotations":[{"id":"23673515-22397653-63233624","span":{"begin":357,"end":359},"obj":"22397653"}],"attributes":[{"subj":"23673515-22397653-63233624","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#ec93c1","default":true}]}]}}